MaxCyte (NASDAQ:MXCT) Upgraded to Hold at Wall Street Zen

MaxCyte (NASDAQ:MXCT) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, MaxCyte presently has a consensus rating of “Hold” and a consensus price target of $7.00.

MaxCyte Price Performance

NASDAQ:MXCT opened at $0.81 on Friday. MaxCyte has a twelve month low of $0.75 and a twelve month high of $4.49. The stock’s 50-day simple moving average is $1.36 and its 200 day simple moving average is $1.53. The firm has a market capitalization of $86.19 million, a PE ratio of -1.84 and a beta of 1.21.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The company had revenue of $6.41 million during the quarter, compared to the consensus estimate of $8.37 million. MaxCyte had a negative return on equity of 23.50% and a negative net margin of 132.57%. On average, analysts anticipate that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. CWM LLC grew its position in shares of MaxCyte by 92.7% in the 2nd quarter. CWM LLC now owns 12,132 shares of the company’s stock valued at $26,000 after buying an additional 5,836 shares during the last quarter. Prudential Financial Inc. bought a new stake in MaxCyte in the second quarter valued at approximately $26,000. May Hill Capital LLC acquired a new stake in MaxCyte during the 2nd quarter valued at approximately $27,000. State of Wyoming bought a new position in MaxCyte during the 2nd quarter worth approximately $38,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of MaxCyte in the 2nd quarter worth approximately $40,000. 68.81% of the stock is owned by institutional investors.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.